JP2018518176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518176A5 JP2018518176A5 JP2017564485A JP2017564485A JP2018518176A5 JP 2018518176 A5 JP2018518176 A5 JP 2018518176A5 JP 2017564485 A JP2017564485 A JP 2017564485A JP 2017564485 A JP2017564485 A JP 2017564485A JP 2018518176 A5 JP2018518176 A5 JP 2018518176A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 431
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 154
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 140
- 210000004027 cell Anatomy 0.000 claims description 99
- 125000000539 amino acid group Chemical group 0.000 claims description 69
- 210000001185 bone marrow Anatomy 0.000 claims description 45
- 210000004443 dendritic cell Anatomy 0.000 claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 239000003446 ligand Substances 0.000 claims description 39
- 210000000274 microglia Anatomy 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 230000009467 reduction Effects 0.000 claims description 27
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 26
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 210000002540 macrophage Anatomy 0.000 claims description 25
- -1 T GF-beta Proteins 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 210000000440 neutrophil Anatomy 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 230000001717 pathogenic effect Effects 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 210000001616 monocyte Anatomy 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 14
- 102000056982 human CD33 Human genes 0.000 claims description 14
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 12
- 210000003714 granulocyte Anatomy 0.000 claims description 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 8
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 8
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 102000043334 C9orf72 Human genes 0.000 claims description 7
- 108700030955 C9orf72 Proteins 0.000 claims description 7
- 229930186217 Glycolipid Natural products 0.000 claims description 6
- 210000004322 M2 macrophage Anatomy 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 108010026424 tau Proteins Proteins 0.000 claims description 5
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 claims description 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 102000007372 Ataxin-1 Human genes 0.000 claims description 4
- 108010032963 Ataxin-1 Proteins 0.000 claims description 4
- 102000002785 Ataxin-10 Human genes 0.000 claims description 4
- 108010043914 Ataxin-10 Proteins 0.000 claims description 4
- 102000007371 Ataxin-3 Human genes 0.000 claims description 4
- 108010032947 Ataxin-3 Proteins 0.000 claims description 4
- 102000007368 Ataxin-7 Human genes 0.000 claims description 4
- 108010032953 Ataxin-7 Proteins 0.000 claims description 4
- 101710147490 Ataxin-8 Proteins 0.000 claims description 4
- 102100026565 Ataxin-8 Human genes 0.000 claims description 4
- 102000014461 Ataxins Human genes 0.000 claims description 4
- 108010078286 Ataxins Proteins 0.000 claims description 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000015833 Cystatin Human genes 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 102400001156 Medin Human genes 0.000 claims description 4
- 101800003015 Medin Proteins 0.000 claims description 4
- 102000016943 Muramidase Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- 108010071690 Prealbumin Proteins 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 102000003946 Prolactin Human genes 0.000 claims description 4
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 4
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 4
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 4
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 4
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 4
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 4
- 102000009190 Transthyretin Human genes 0.000 claims description 4
- 108090000848 Ubiquitin Proteins 0.000 claims description 4
- 102000044159 Ubiquitin Human genes 0.000 claims description 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 4
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 4
- 108700006666 betaIG-H3 Proteins 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 4
- 108050004038 cystatin Proteins 0.000 claims description 4
- 229960000578 gemtuzumab Drugs 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 102000013498 tau Proteins Human genes 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 102000007370 Ataxin2 Human genes 0.000 claims description 3
- 108010032951 Ataxin2 Proteins 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 101150014718 C9orf72 gene Proteins 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 3
- 102000009109 Fc receptors Human genes 0.000 claims description 3
- 102000004878 Gelsolin Human genes 0.000 claims description 3
- 108090001064 Gelsolin Proteins 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000004558 lewy body Anatomy 0.000 claims description 3
- 229950002950 lintuzumab Drugs 0.000 claims description 3
- 102000005912 ran GTP Binding Protein Human genes 0.000 claims description 3
- 108010005597 ran GTP Binding Protein Proteins 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 2
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 101150065475 C1QA gene Proteins 0.000 claims description 2
- 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 claims description 2
- 108010017009 CD11b Antigen Proteins 0.000 claims description 2
- 102100035904 Caspase-1 Human genes 0.000 claims description 2
- 102100031237 Cystatin-A Human genes 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims description 2
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 claims description 2
- 101000896583 Homo sapiens C3a anaphylatoxin chemotactic receptor Proteins 0.000 claims description 2
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 claims description 2
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 claims description 2
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 claims description 2
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102100034238 Linker for activation of T-cells family member 2 Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100038556 Membrane-spanning 4-domains subfamily A member 4A Human genes 0.000 claims description 2
- 108091006236 SLC7A7 Proteins 0.000 claims description 2
- 108091006238 SLC7A8 Proteins 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 101150069237 TYROBP gene Proteins 0.000 claims description 2
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 102100032726 Y+L amino acid transporter 1 Human genes 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 210000000225 synapse Anatomy 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 231100001221 nontumorigenic Toxicity 0.000 description 51
- 238000000034 method Methods 0.000 description 49
- 206010028980 Neoplasm Diseases 0.000 description 43
- 210000002798 bone marrow cell Anatomy 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 230000001506 immunosuppresive effect Effects 0.000 description 17
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 230000005909 tumor killing Effects 0.000 description 8
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 7
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- 210000003289 regulatory T cell Anatomy 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 6
- 102100038078 CD276 antigen Human genes 0.000 description 6
- 101710185679 CD276 antigen Proteins 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 5
- 210000002997 osteoclast Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102100031351 Galectin-9 Human genes 0.000 description 4
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102000017761 Interleukin-33 Human genes 0.000 description 4
- 108010043610 KIR Receptors Proteins 0.000 description 4
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 4
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 108091006374 cAMP receptor proteins Proteins 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102210009321 rs3865444 Human genes 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 3
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 3
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229960004117 capecitabine Drugs 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940087477 ellence Drugs 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- 229940063683 taxotere Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 108010066676 Abrin Proteins 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101710155855 C-C motif chemokine 4 Proteins 0.000 description 2
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 2
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 2
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102100031942 Oncostatin-M Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 108090000681 interleukin 20 Proteins 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 230000000722 protumoral effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102220556120 Myeloid cell surface antigen CD33_A14V_mutation Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 description 1
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 description 1
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- QCHRAZFMQXDSSF-ZTOGJOBFSA-N ang 1005 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)NC(C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 QCHRAZFMQXDSSF-ZTOGJOBFSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175152P | 2015-06-12 | 2015-06-12 | |
| US62/175,152 | 2015-06-12 | ||
| US201562241701P | 2015-10-14 | 2015-10-14 | |
| US62/241,701 | 2015-10-14 | ||
| PCT/US2016/037108 WO2016201388A2 (en) | 2015-06-12 | 2016-06-11 | Anti-cd33 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020161867A Division JP2021019599A (ja) | 2015-06-12 | 2020-09-28 | 抗ｃｄ３３抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518176A JP2018518176A (ja) | 2018-07-12 |
| JP2018518176A5 true JP2018518176A5 (enExample) | 2019-07-18 |
| JP7376977B2 JP7376977B2 (ja) | 2023-11-09 |
Family
ID=56204010
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564485A Active JP7376977B2 (ja) | 2015-06-12 | 2016-06-11 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2020161867A Withdrawn JP2021019599A (ja) | 2015-06-12 | 2020-09-28 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2022098925A Pending JP2022137076A (ja) | 2015-06-12 | 2022-06-20 | 抗ｃｄ３３抗体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020161867A Withdrawn JP2021019599A (ja) | 2015-06-12 | 2020-09-28 | 抗ｃｄ３３抗体及びその使用方法 |
| JP2022098925A Pending JP2022137076A (ja) | 2015-06-12 | 2022-06-20 | 抗ｃｄ３３抗体及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11136390B2 (enExample) |
| EP (1) | EP3307771A2 (enExample) |
| JP (3) | JP7376977B2 (enExample) |
| KR (1) | KR20180033502A (enExample) |
| CN (2) | CN107922480B (enExample) |
| AU (1) | AU2016276981B2 (enExample) |
| CA (1) | CA2988982A1 (enExample) |
| SG (1) | SG10201912085WA (enExample) |
| WO (1) | WO2016201388A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| US12024560B2 (en) | 2017-03-28 | 2024-07-02 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3625258A1 (en) | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| WO2018218207A1 (en) * | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| BR112020000357A2 (pt) * | 2017-07-08 | 2020-07-21 | The General Hospital Corporation | plataforma de triagem para identificar fármacos ou agentes terapêuticos para o tratamento da doença de alzheimer |
| MY205541A (en) | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JP2021028293A (ja) * | 2017-09-21 | 2021-02-25 | 第一三共株式会社 | 免疫抑制性ミエロイド細胞マーカー |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091976A1 (ru) * | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| SG11202100555PA (en) | 2018-07-27 | 2021-02-25 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| CN109112215A (zh) * | 2018-08-02 | 2019-01-01 | 广州安镝声生物医药科技有限公司 | lncRNA H19的靶蛋白FUS及其应用 |
| AR119259A1 (es) | 2018-08-31 | 2021-12-09 | Alector Llc | Anticuerpos anti-cd33 y métodos de uso de los mismos |
| JP2022501319A (ja) * | 2018-09-25 | 2022-01-06 | アカデミア シニカAcademia Sinica | 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| AU2020225631A1 (en) * | 2019-02-22 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| CA3136453A1 (en) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Humanized anti-pd-l1 antibodies |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| MX2022001882A (es) * | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| WO2021119400A1 (en) * | 2019-12-12 | 2021-06-17 | Alector Llc | Methods of use of anti-cd33 antibodies |
| CA3173213A1 (en) * | 2020-03-31 | 2021-10-07 | Roland B. WALTER | Anti-cd33 antibodies and uses thereof |
| EP4126248A4 (en) | 2020-03-31 | 2024-07-10 | Fred Hutchinson Cancer Center | HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES |
| AU2021260960A1 (en) * | 2020-04-22 | 2022-11-24 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| WO2022234003A1 (en) * | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| CN113444687A (zh) * | 2021-05-31 | 2021-09-28 | 浙江圣希澳医学科技有限公司 | 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法 |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| GB202202171D0 (en) * | 2022-02-17 | 2022-04-06 | Bivictrix Ltd | Novel methods of therapy |
| CN114774468B (zh) * | 2022-04-20 | 2022-12-20 | 温氏食品集团股份有限公司 | 一种等位基因分子标记及抗蓝耳病猪群体组建方法 |
| CN119403834A (zh) * | 2022-04-21 | 2025-02-07 | 中国抗体制药有限公司 | 治疗神经系统疾病的方法 |
| CN117752813A (zh) * | 2022-09-26 | 2024-03-26 | 成都百利多特生物药业有限责任公司 | 抗cd33抗体和抗cd33抗体-药物偶联物及其用途 |
| IL320040A (en) * | 2022-10-05 | 2025-06-01 | Musc Found For Res Dev | Superantigen conjugate vaccine for cancer treatment |
| WO2024103050A1 (en) * | 2022-11-11 | 2024-05-16 | The United States Government As Represented By The Department Of Veterans Affairs | Hbv specific exosomes and uses thereof |
| AU2024249778A1 (en) * | 2023-04-03 | 2025-11-06 | Alchemab Therapeutics Ltd | Anti-cd33 antibodies |
| JP2026516593A (ja) * | 2023-04-03 | 2026-05-26 | ウニバズィテート バーゼル | 細胞治療に使用するためのｃｄ３３の識別可能な表面タンパク質変異体 |
| WO2024219897A1 (ko) * | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| CN118580357A (zh) * | 2024-08-07 | 2024-09-03 | 上海交通大学医学院附属仁济医院 | 一种cd33特异性单克隆抗体及其应用 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US769571A (en) | 1904-04-12 | 1904-09-06 | George W Snyder | Adjustable swinging gate. |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| EP0504327B1 (en) | 1989-12-14 | 2000-09-20 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| AU684748B2 (en) | 1993-01-21 | 1998-01-08 | Hybridon, Inc. | Foldback triplex-forming oligonucleotides |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
| US6140482A (en) | 1995-06-01 | 2000-10-31 | Hybridon, Inc. | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
| US5614622A (en) | 1995-06-01 | 1997-03-25 | Hybridon, Inc. | 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses |
| US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
| US5637683A (en) | 1995-07-13 | 1997-06-10 | Cornell Research Foundation, Inc. | Nucleic acid analog with amide linkage and method of making that analog |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6117992A (en) | 1996-08-26 | 2000-09-12 | Hybridon, Inc. | Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145496A0 (en) | 1999-03-24 | 2002-06-30 | Exiqon As | Improved synthesis of [2.2.1] bicyclo nucleosides |
| KR20010001577A (ko) | 1999-06-07 | 2001-01-05 | 윤종용 | 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법 |
| AU6629200A (en) | 1999-08-25 | 2001-03-19 | Philip P Garner | Alpha-helical peptide nucleic acid alpha-pna |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200726776A (en) | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20110038856A1 (en) | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| AU2010298036B2 (en) | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2012074097A1 (ja) | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗ｃｄ３３抗体 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN102952191B (zh) | 2012-09-17 | 2014-05-14 | 浙江大学 | 全人源抗cd33单链抗体zjl101及其应用 |
| EP2978446B1 (en) * | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| AU2015357054A1 (en) * | 2014-12-04 | 2017-06-29 | Abruzzo Theranostic S.R.L. | Humanized anti-Trop-2 monoclonal antibodies and uses thereof |
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| MY205541A (en) | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
-
2016
- 2016-06-11 AU AU2016276981A patent/AU2016276981B2/en active Active
- 2016-06-11 CN CN201680047246.1A patent/CN107922480B/zh active Active
- 2016-06-11 EP EP16732131.4A patent/EP3307771A2/en not_active Withdrawn
- 2016-06-11 CA CA2988982A patent/CA2988982A1/en not_active Abandoned
- 2016-06-11 SG SG10201912085WA patent/SG10201912085WA/en unknown
- 2016-06-11 US US15/735,947 patent/US11136390B2/en active Active
- 2016-06-11 JP JP2017564485A patent/JP7376977B2/ja active Active
- 2016-06-11 CN CN202211041145.7A patent/CN116063499A/zh active Pending
- 2016-06-11 KR KR1020187000654A patent/KR20180033502A/ko not_active Ceased
- 2016-06-11 WO PCT/US2016/037108 patent/WO2016201388A2/en not_active Ceased
-
2020
- 2020-09-28 JP JP2020161867A patent/JP2021019599A/ja not_active Withdrawn
-
2021
- 2021-08-27 US US17/459,835 patent/US20220251190A1/en active Pending
-
2022
- 2022-06-20 JP JP2022098925A patent/JP2022137076A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023022036A5 (enExample) | ||
| JP2018518491A5 (enExample) | ||
| JP2018525999A5 (enExample) | ||
| JP7132232B2 (ja) | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 | |
| JP2020500540A5 (enExample) | ||
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| US12331119B2 (en) | Modified Fc fragment, antibody comprising same, and application thereof | |
| AU2013361275B2 (en) | Anti-human B7-H4 antibodies and their uses | |
| IL301956A (en) | Antibodies against dectin-1 and methods of using them | |
| JP2021525082A5 (enExample) | ||
| TW202208429A (zh) | 用於治療多發性骨髓瘤之方法 | |
| KR20190091330A (ko) | 항-sirp-알파 항체 및 그의 사용 방법 | |
| US11884725B2 (en) | Antibody against TIM-3 and application thereof | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| JP7745556B2 (ja) | Ｃｄ１３７結合分子及びその使用 | |
| JP2021531027A5 (enExample) | ||
| AU2022332499A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| US20240124598A1 (en) | Anti-CD30 monoclonal antibodies and chimeric antigen receptors | |
| JP2025504012A (ja) | 抗ｂｔｌａ抗体および癌治療におけるその使用 | |
| KR20260071841A (ko) | 다중특이적 항체 및 이의 용도 | |
| WO2025064951A1 (en) | Anti-tumor antibodies | |
| CN118302200A (zh) | 用于治疗癌症的b7-h4抗体-药物缀合物 | |
| CN116724054A (zh) | 抗Dectin-1抗体和其使用方法 |